Press release
Systemic Lupus Erythematosus Pipeline Insight: 120+ Pharma Companies Advance 140+ Novel SLE and CLE Therapies, Finds DelveInsight | Biogen, Novartis, Idorsia Pharmaceuticals, Genentech, Evergreen Therapeutics
Systemic Lupus Erythematosus Pipeline
Explore the latest breakthroughs in the Systemic Lupus Erythematosus treatment landscape. Learn more about the evolving SLE pipeline today @ https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Key Takeaways from the Systemic Lupus Erythematosus Pipeline Report
• In April 2026, DelveInsight released its updated analysis of the SLE clinical trial pipeline, showing accelerated development with 120+ pharma companies rigorously developing drugs for market entry.
• In March 2026, Genentech announced that detailed Phase III ALLEGORY trial results for Gazyva (obinutuzumab) in adults with SLE were published in the New England Journal of Medicine.
• In March 2026, Johnson & Johnson's nipocalimab was granted U.S. FDA Fast Track designation as a potential treatment for adults with systemic lupus erythematosus.
• In January 2026, the FDA granted Breakthrough Therapy Designation to Biogen's litifilimab (BIIB059) for the treatment of cutaneous lupus erythematosus (CLE).
• In September 2025, AstraZeneca reported positive high-level results from the Phase III TULIP-SC trial, where subcutaneous Saphnelo (anifrolumab) met its primary endpoint in SLE patients.
• In September 2024, UCB and Biogen announced successful results from the Phase III PHOENYCS GO study evaluating dapirolizumab pegol in patients with moderate-to-severe SLE.
• Evergreen Therapeutics reported success in the Phase 2 ClearMEMory trial for EG501, which demonstrated significant improvement in cognitive function, or "brain fog," in SLE patients.
• The leading Systemic Lupus Erythematosus companies include Biogen, Novartis, Idorsia Pharmaceuticals, Genentech, AstraZeneca, Viatris, Evergreen Therapeutics, and Dianthus.
• Promising therapies in development include litifilimab, obinutuzumab, cenerimod, EG501, LBL-047, and dapirolizumab pegol.
Download for updates and the latest revolution in SLE care @ https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Systemic Lupus Erythematosus Emerging Drugs Profile
• Litifilimab (BIIB059): Biogen
Litifilimab is a first-in-class, humanized IgG1 monoclonal antibody targeting blood dendritic cell antigen 2 (BDCA2), expressed on plasmacytoid dendritic cells (pDCs). It is designed to selectively inhibit the production of type 1 interferons and other inflammatory mediators. Litifilimab is currently being evaluated in Phase III trials for SLE and has received Breakthrough Therapy Designation for CLE. By inhibiting BDCA2 on specific cells, it aims to provide a safer mechanism than broad interferon blockade.
• EG501: Evergreen Therapeutics
EG501 is a small-molecule oral tablet that acts as an NMDA receptor antagonist, specifically repurposed to treat "brain fog" or cognitive dysfunction in lupus. Researchers identified that overactivity of NMDA receptors, linked to a genetic variation in SLE patients, contributes to memory and attention impairments. In the Phase 2 ClearMEMory trial, EG501 demonstrated significant cognitive improvement over 12 weeks. Evergreen Therapeutics is currently preparing for a Phase 3 clinical trial to further validate its efficacy.
• LBL-047 (DNTH212): Dianthus / Leads Biolabs
LBL-047 is a bifunctional fusion protein targeting pDC BDCA2 to reduce type 1 interferon production while simultaneously inhibiting BAFF and APRIL to suppress B cell function. By targeting both the innate and adaptive immune systems, it addresses multiple drivers of autoimmune disease. A Phase 1 study in SLE patients was initiated in December 2025, with top-line results in healthy volunteers expected in the second half of 2026. LBL-047 has been optimized with Fc engineering for subcutaneous self-administration every four weeks or less.
For more information on the Systemic Lupus Erythematosus Emerging Drugs Profile, download DelveInsight's comprehensive Systemic Lupus Erythematosus Pipeline Insight report @ https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
The Systemic Lupus Erythematosus Pipeline Report Provides
• Detailed insights about 120+ companies developing therapies for SLE, with aggregate therapies developed by each.
• Therapeutic candidates segmented into early-stage, mid-stage, and late-stage (Phase III) development for SLE and CLE treatment.
• Detailed analysis of the interferon pathway, B cell activation, and JAK inhibition as central mechanisms in recent advancements.
• Drug assessment based on route of administration, target receptor, monotherapy or combination therapy, and molecular type.
• Thorough analysis of collaborations, licensing agreements, and financing, such as the $1 billion partnership between Dianthus and Leads Biolabs.
Learn more about Systemic Lupus Erythematosus drug opportunities in our comprehensive SLE pipeline report @ https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Systemic Lupus Erythematosus Companies and Competitive Landscape
There are 120+ key companies, including Biogen, Novartis, Idorsia, Genentech, AstraZeneca, and Viatris, developing therapies for SLE. Biogen and Idorsia have candidates in advanced Phase III stages.
DelveInsight's Systemic Lupus Erythematosus pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration, including:
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Systemic Lupus Erythematosus products have been categorized under various Molecule types such as:
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Discover the latest advancements in Systemic Lupus Erythematosus treatment by visiting our website. Stay informed @ https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Scope of the Systemic Lupus Erythematosus Pipeline Report
• Coverage: Global
• SLE Companies: Biogen, Novartis, Idorsia, Roche, AstraZeneca, Viatris, Evergreen Therapeutics, and others.
• SLE Therapies: litifilimab, cenerimod, EG501, LBL-047, and dapirolizumab pegol.
• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III.
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe, helping them stay ahead of the growth curve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Systemic Lupus Erythematosus Pipeline Insight: 120+ Pharma Companies Advance 140+ Novel SLE and CLE Therapies, Finds DelveInsight | Biogen, Novartis, Idorsia Pharmaceuticals, Genentech, Evergreen Therapeutics here
News-ID: 4505234 • Views: …
More Releases from DelveInsight Business Research
Retinitis Pigmentosa Pipeline 2026: FDA Approvals and Clinical Trials Landscape …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Retinitis Pigmentosa pipeline constitutes 20+ key companies continuously working towards developing 25+ Retinitis Pigmentosa treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Retinitis Pigmentosa Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Retinitis Pigmentosa Market.
The Retinitis…
Multiple Sclerosis Pipeline 2026: Therapies, MOA Insights, and Key Clinical Tria …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Multiple Sclerosis pipeline constitutes 75+ key companies continuously working towards developing 80+ Multiple Sclerosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Multiple Sclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also…
Car T Cell Therapy For Multiple Myeloma Pipeline 2026: MOA, ROA, FDA-Approved Dr …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Car T Cell Therapy For Multiple Myeloma pipeline constitutes 5+ key companies continuously working towards developing 5+ Car T Cell Therapy For Multiple Myeloma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Car T Cell Therapy For Multiple Myeloma Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into…
Spinocerebellar Ataxias Pipeline 2026: Therapies Under Investigation, Clinical T …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Spinocerebellar Ataxias pipeline constitutes 8+ key companies continuously working towards developing 10+ Spinocerebellar Ataxias treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Spinocerebellar Ataxias Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinocerebellar Ataxias Market.
The Spinocerebellar…
More Releases for Systemic
Leading Industry Participants Reinforce Their Presence in the Systemic Aspergill …
The systemic aspergillosis and systemic candidiasis market is on track for substantial expansion over the coming years, driven by advancements in antifungal treatments and growing medical needs. As healthcare continues to evolve, the demand for more effective and targeted therapies in managing these fungal infections is increasing, setting the stage for promising developments in this sector.
Projected Growth Outlook for the Systemic Aspergillosis and Systemic Candidiasis Market
The market for…
What Is Driving Global Systemic Aspergillosis And Systemic Candidiasis Market Gr …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Systemic Aspergillosis And Systemic Candidiasis Market Size Growth Forecast: What to Expect by 2025?
The market valuation for systemic aspergillosis and systemic candidiasis has experienced consistent upward momentum across recent years, projected to advance from a figure of $7.24 billion in 2024 to reach $7.57 billion by 2025, reflecting…
Transformative Trends Impacting the Systemic Aspergillosis And Systemic Candidia …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Systemic Aspergillosis And Systemic Candidiasis Market Size By 2025?
The growth trend of the systemic aspergillosis and systemic candidiasis market has been steadily ascending in the past few years. The market size will inflate from $7.24 billion in 2024 to $7.59 billion in 2025, indicating…
Systemic Aspergillosis And Systemic Candidasis Market Size by Type, Application, …
According to Market Research Intellect, the global Systemic Aspergillosis And Systemic Candidasis market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The growing prevalence of invasive fungal infections, especially in immunocompromised persons, is propelling the global…
Systemic Aspergillosis and Systemic Candidiasis Treatment Market - Industry Over …
The systemic aspergillosis and systemic candidiasis treatment market is gaining significant attention within the global healthcare and pharmaceutical industries due to the increasing incidence of life-threatening fungal infections among immunocompromised individuals. Both systemic aspergillosis and systemic candidiasis are opportunistic fungal infections, often affecting patients with weakened immune systems due to cancer therapy, organ transplantation, HIV/AIDS, or intensive care treatments.
The systemic aspergillosis and systemic candidiasis treatment market was valued at approximately…
Systemic Aspergillosis and Systemic Candidiasis Market Share, Sales Channels and …
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
The systemic aspergillos is and systemic candidiasis market is expected to reach US$ 8,247.5 million by 2027 from US$ 6,056.3 million in 2019. The market is estimated to grow at a CAGR of 4.0% from 2020 to 2027.
To get sample Copy of the report, along with…
